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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitis, emphysema
and irreversible airflow limitation. These changes are thought to be due to oxidative stress and an imbalance of
proteases and antiproteases. Quercetin, a plant flavonoid, is a potent antioxidant and anti-inflammatory agent. We
hypothesized that quercetin reduces lung inflammation and improves lung function in elastase/lipopolysaccharide
(LPS)-exposed mice which show typical features of COPD, including airways inflammation, goblet cell metaplasia,
and emphysema.
Methods: Mice treated with elastase and LPS once a week for 4 weeks were subsequently administered 0.5 mg of
quercetin dihydrate or 50% propylene glycol (vehicle) by gavage for 10 days. Lungs were examined for elastance,
oxidative stress, inflammation, and matrix metalloproteinase (MMP) activity. Effects of quercetin on MMP
transcription and activity were examined in LPS-exposed murine macrophages.
Results: Quercetin-treated, elastase/LPS-exposed mice showed improved elastic recoil and decreased alveolar
chord length compared to vehicle-treated controls. Quercetin-treated mice showed decreased levels of
thiobarbituric acid reactive substances, a measure of lipid peroxidation caused by oxidative stress. Quercetin also
reduced lung inflammation, goblet cell metaplasia, and mRNA expression of pro-inflammatory cytokines and
muc5AC. Quercetin treatment decreased the expression and activity of MMP9 and MMP12 in vivo and in vitro,
while increasing expression of the histone deacetylase Sirt-1 and suppressing MMP promoter H4 acetylation.
Finally, co-treatment with the Sirt-1 inhibitor sirtinol blocked the effects of quercetin on the lung phenotype.
Conclusions: Quercetin prevents progression of emphysema in elastase/LPS-treated mice by reducing oxidative
stress, lung inflammation and expression of MMP9 and MMP12.
Background
Chronic obstructive pulmonary disease (COPD) is a het-
erogeneous disorder characterized by small airway
inflammation/fibrosis, mucus plugging and emphysema.
COPD is the fourth leading cause of death worldwide
and the prevalence is predicted to rise in the next two
decades [1].
Although the cellular and molecular mechanisms of
COPD pathogenesis are not well known, oxidative
stress, chronic inflammation and an imbalance of pro-
teases and antiproteases are thought to play key roles in
development and progression of the disease [1]. There-
fore, a treatment with antioxidant and anti-inflammatory
properties could be beneficial in preventing or slowing
the progression of lung disease in COPD.
Inhalation of cigarette smoke and other environmental
exposures can stimulate resident alveolar macrophages
and lung epithelial cells to generate reactive oxygen spe-
cies (ROS) and reactive nitric oxide species (RNS) in
excess, thereby disturbing the oxidant to antioxidant
balance, resulting in oxidative stress [2-4]. ROS and
RNS stimulate the production of a number of host
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mediators, some of which can attract neutrophils,
macrophages and other inflammatory cells to the lungs.
Recruited inflammatory cells and epithelial cells produce
matrix metalloproteinases (MMPs), thereby increasing
protease activity in the lungs. MMPs, in turn, degrade
alveolar walls, leading to enlargement of airspace and
development of emphysema. In addition, chronic inflam-
mation causes remodeling of the airways, including gob-
let cell metaplasia, mucus plugging and airway wall
thickening.
The histone deacetylases (HDACs) are transcriptional
repressors which have been implicated in the resolution
of inflammation as well as the regulation of MMP
expression [5]. In COPD patients, reductions in the
expression of HDAC2 and HDAC5 correlate with dis-
ease severity and increased IL-8 expression [6]. Simi-
larly, the type III HDAC Sirt1, which regulates MMP
expression, was also found to be downregulated in
COPD [7].
Lipopolysaccharide (LPS), a cell wall component of
gram negative bacteria, is a potent inflammatory mole-
cule and is present in appreciable amounts in cigarette
smoke. It is also an active component in environmental
and occupational exposures associated with the develop-
ment of COPD [8-10]. Experimental inhalation of LPS
evokes pulmonary and systemic inflammation in healthy
human subjects [11,12]. Chronic exposure of experimen-
tal animals causes emphysema, goblet cell metaplasia,
and airway wall thickening. These alterations persist up
to four to eight weeks following LPS administration
[13,14]. Recently, we demonstrated that mice exposed to
a combination of LPS and elastase once a week for 4
weeks display COPD-like features including widespread
lung inflammation, goblet cell metaplasia, increased lung
volume, emphysema and decreased elastic recoil [15].
These changes persisted up to 8 weeks after cessation of
exposure to elastase and LPS. These mice were also
found to be more susceptible for rhinovirus infection.
Quercetin is a 3,3’,4’,5,7-pentahydroxyflavone found in
many plants. Based on its polyphenol structure, querce-
tin has potent antioxidant effects, combining with free
radical species to form considerably less reactive phe-
noxy radicals [16,17]. Quercetin also has anti-inflamma-
tory effects, inhibiting lipid, protein tyrosine and serine/
threonine kinases by its capacity to compete with the
binding of ATP at the nucleotide binding site [18]. Pre-
viously, we demonstrated that quercetin inhibits TNF-a
stimulated IL-8 expression at the transcriptional level in
airway epithelial cells and decreases airways hyperre-
sponsiveness in cockroach allergen-sensitized and chal-
lenged mice, a model of allergic airways disease, at a
dose of 0.6 mg per day (approximately 30 mg/kg body
weight) [19]. Quercetin was also shown to suppress eosi-
nophilic inflammation in ovalbumin-sensitized and
-challenged mice at a dose of 10 mg/kg body weight
[20]. Further, quercetin decreases the expression of
MMP9 stimulated by TNF-a in epidermal cells [21].
Based on these observations, we hypothesized that quer-
cetin reverses oxidative stress and inhibit MMP produc-
tion, perhaps by increasing the expression of the histone
deacetylase Sirt-1, thereby preventing the progression of
lung disease in COPD. To test this hypothesis, we trea-
ted elastase/LPS exposed mice with quercetin (10 mg/kg
body weight), and examined oxidative stress, inflamma-
tion and expression of MMP9, MMP12 and SIRT-1 in
the lungs. We also determined the effect of quercetin on
the histone acetylation of the MMP9 and MMP12 pro-
moters by chromatin immunoprecipitation assay.
Methods
Animals and treatment
Eight to ten weeks old C57BL/6 mice (Charles River
Laboratories International Inc., Wilmington, MA) were
exposed to elastase and LPS for four consecutive weeks
as described previously [15]. Animals were exposed by
the intranasal route to 1.2 U of porcine pancreatic elas-
tase (Elastin Products, Owensville, MO) on day one and
7 μg (approximately 70 endotoxin units) of LPS from
E. coli O26:B6 (Sigma-Aldrich, St. Louis, MO) on day
four of the week for four consecutive weeks. Control
mice were exposed to PBS. Seven days after the last
exposure to LPS, mice were orally gavaged with 300 μl
of 50% propylene glycol (vehicle) or 0.2 mg of quercetin
(10 mg/kg body weight; Sigma-Aldrich, St. Louis, MO)
dissolved in 50% propylene glycol, once a day for 10
days. We chose this dose of quercetin based on previous
studies in which quercetin at 10 mg/kg body weight
reduced airways responsiveness and lung inflammation
in an allergic mouse model of asthma [19,20]. In some
experiments, mice were treated intraperitoneally with
100 μl PBS or PBS containing sirtinol (0.5 mg/kg body
weight, Calbiochem, Gibbstown, NJ) along with querce-
tin or vehicle for 10 days. Mice were sacrificed 1 h after
the last quercetin treatment. In some experiments, mice
were examined 7 and 17 days after the last exposure to
LPS without any treatment in order to examine the pro-
gression of emphysema after cessation of exposure to
elastase/LPS. Unexposed mice treated with vehicle or
quercetin (10 mg/kg body weight) were used as negative
controls. All experiments described herein were
approved by the Animal Care and Use Committee of
the University of Michigan.
Measurement Of Lung Elasticity
Mice Were Anesthetized By Intraperitoneal Injection Of
Ketamine (2.5-5 Mg/100 G Body Weight) And A Steel
Cannula Was Inserted Into The Trachea And Con-
nected To A Miniature Computerized Flexivent
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Ventilator (Scireq, Montreal, Quebec, Canada). Sodium
Pentabarbitol (2 Mg/100 G Body Weight) Was Also
Given To Provide Further Sedation And Allow Stabiliza-
tion On The Ventillator. To Determine Elastic Recoil,
Lungs Were Gradually Inflated To 30 Cm H2O And
Pressure And Lung Volume Measured Continuously
During Inflation And Deflation Of The Lungs. Static
Elastance And Compliance Were Recorded By Inflating
The Lungs To Full Capacity.
Lung Histology And Morphometry
Lungs Were Perfused With 20 Mm Edta And Inflation-
Fixed With 10% Buffered Formalin, And Embedded In
Paraffin. Five Micron Thick Sagittal Sections Were
Stained With Hematoxylin And Eosin (H & E) Or Peri-
odic-Acid Schiff’(Pas) Reagent. Alveolar Chord Length
Was Determined Using Sagittal Sections Obtained At
5 Mm Intervals Through The Length Of The Lungs,
And Diameter Of The Airspaces Was Measured In Ran-
dom Areas Using Nih Image J Analysis Software [15].
Bronchoalveolar Lavage (Bal)
Mice Were Euthanized And Lungs Were Lavaged With
Pbs. Bal Fluid Was Centrifuged And The Supernatant
Was Collected For Determination Of Mmp Levels. Total
And Differential Cell Counts In Bal Fluid Were Deter-
mined As Described Previously [15,22].
Lung Cytokine Levels
After Relevant Treatment, Mice Were Euthanized,
Lungs Were Collected, Homogenized In Pbs Containing
Complete Protease Inhibitors And Centrifuged (Roche,
Indianapolis, In). Cytokine Protein Levels In The Lung
Homogenate Supernatants Were Measured Either By
Elisa (R & D Systems, Minneapolis, Mn) Or Multiplex
Immunoassay (Biorad, Hercules, Ca) [15,22].
Alveolar Macrophage Cell Culture
Murine Alveolar Macrophages (Crl-2019, American
Type Culture Collection, Manassas, Va) Were Cultured
In Rpmi1640 Supplemented With 10% Fetal Bovine
Serum, Penicillin (100 Units/Ml), Streptomycin (100 μG/
Ml), 1% Glutamine And 0.01% b-Mercaptoethanol. To
Determine The Effect Of Quercetin On Mmp Expres-
sion, Cells Were Seeded In 6 Well Plates And Grown
For 24 H. Cells Were Then Exposed To Cell Culture
Media Containing 1 Ng/Ml Lps For 8 Hours A Day
For Three Days. In Between Exposures To Lps, Cells
Were Maintained In Cell Culture Media Alone. Cells
Were Then Shifted To Serum-Free Media Containing
Quercetin Dihydrate Or Dmso, Incubated For 24 H,
And Media And Cells Were Harvested. Cells Exposed
To Media Alone Instead Of Lps Were Used As Nega-
tive Controls.
Gelatin Zymography
Mmp Activity Was Determined By Gelatin Zymography
As Described.[23]. Briefly, Equal Volumes Of Bal Super-
natant Or Conditioned Cell Culture Media Was Incu-
bated With Non-Reducing Sample Buffer And Subjected
To Electrophoresis On 8% Polyacrylamide Gels Impreg-
nated With 0.1% Gelatin. Gels Were Washed With 1%
Triton X-100, Developed In Tris Buffer Containing
10 Mm Cacl2 And 5μM Zncl2 And Stained With 0.5%
Coomassie Blue.
Measurement Of Plasma Quercetin Levels
Mice Were Sacrificed And Blood Was Collected By Car-
diac Puncture In Tubes With Anticoagulant, Centri-
fuged And Plasma Was Collected. Levels Of Quercetin
In Plasma Were Determined By Hplc As Described Pre-
viously [19].
Chromatin Immunoprecipitation (Chip) Assay
Chip Assays Were Performed With A Chip-It Kit
(Active Motif, Carlsbad, Ca) Following The Manufac-
turer’S Instructions. Briefly, Cells Were Fixed, Lysed
And Chromatin Was Subjected To Enzymatic Shear-
ing. Chromatin Fragments Of 100-1000 Bp Were
Immunoprecipitated With An Antibody To Acetylhis-
tone H4 Antibody. Chip And Input Dna Were Purified
And Subjected To Qpcr Using Primers Specific For
The Nf-B Binding Site In The Mmp9 And Mmp12
Promoters. Qpcr Conditions Were As Follows: 95°C
For 15 Minutes; 95°C For 10 Seconds, 60°C For 30
Seconds, 72°C For 30 Seconds, Repeated For 50 Cycles,
72°C For 10 Minutes. The Primers Used For Qpcr
Were Mmp9: Sense 5’-TTTAAACAGAAGAGGAAG-
GAT AGTGC-3 ’ And Antisense 5’-CCTGATA-




Expression Of Mmp9, Mmp12, Sirt1, Inducible Nitric
Oxide Synthase (Inos), Heme Oxygenase (Hmox)-1, And
Muc5Ac Was Determined By Qpcr. All Pcr Reactions
Were Performed In An Eppendorf Mastercycler (West-
bury, Ny) And Gene Expression Was Quantified Using
The Comparative Ct Method.
Western Blotting
Nuclear Proteins Were Resolved By 7.5% Sds-Polyacryla-
mine Gel Electrophoresis, Proteins Transferred To Nitro-
cellulose Membrane And Probed With Antibody To Sirt1
And b-Actin (Santa Cruz Biotechnology, Santa Cruz, Ca).
Specific Bands Were Quantified By Densitometry Using
Nih Imagej And Expressed As A Ratio Of Sirt1/B-Actin
Which Is Normalized To Untreated Control Mice.
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Lipid Peroxidation
The Amount Of Lipid Peroxidation Products In The
Lungs Was Assayed As Thiobarburtic Acid Reacting
Substances (Tbars) (Cell Biolabs, San Diego, Ca) Follow-
ing Manufacturer’S Instructions.
Statistical Analysis
Statistical Analysis Of Significance Was Calculated By
One-Way Analysis Of Variance Followed By Tukey’S
Post Hoc Test, Anova On Ranks With Dunn’S Post Hoc
Analysis Or By Mann-Whitney Test As Appropriate.
Results Represent Mean ± Sd Or Sem, Or Range Of
Data With Median.
Results
Effect of quercetin on elastase/LPS-induced emphysema
As observed previously [15], mice at seven days after the
four-week exposure to elastase/LPS showed an upward
and leftward shift compared to control mice, demonstra-
tive of reduced elastic recoil (Figure 1A). Because mice
receiving quercetin or vehicle for 10 days were studied a
total of 17 days after the last exposure to elastase/LPS,
we also measured the lung function of untreated mice
at this time point. The volume-pressure curve was
shifted further to the left, indicating further progression
of emphysema after cessation of exposure to elastase/
LPS. This shift may be due to persistence of oxidative
stress and MMP activity even after cessation of exposure
to elastase/LPS. This situation is analogous to the
further progression of emphysema in COPD patients
even after cessation of smoking [24].
Next, we examined the lung function of mice treated
with quercetin (0.2 mg) or vehicle for 10 days starting
one week after the four-week course of elastase/LPS-
treatment. Compared to vehicle, mice receiving querce-
tin showed a rightward and downward shift in their
volume-pressure curve (Figure 1B). Shifts in the pres-
sure-volume loops were accompanied by appropriate
changes in elastance and compliance (Figures 1C and
1D). Finally, compared to vehicle, quercetin treatment
was associated with a reduction in alveolar chord length
(Figure 1E). However, quercetin treatment did not com-
pletely reverse the emphysematous changes caused by
elastase/LPS. Quercetin treatment did not affect any of
these measurements in the lungs of mice exposed to
PBS. Together, these data suggest that quercetin treat-
ment prevented further progression of emphysema after
elastase/LPS treatment rather than stimulating the
regeneration of degraded alveoli.
Quercetin decreases oxidative stress in
elastase/LPS-exposed mice
To determine the mechanism by which quercetin pre-
vents progression of emphysema in elastase/LPS-
treated mice, we examined the effects of quercetin on
indices of lung oxidative stress and inflammation.
Elastase/LPS-exposed mice were treated with 0.2 mg
of quercetin for 10 days and lung levels of TBARS,
iNOS mRNA and Hmox-1 mRNA determined. Com-
pared to unexposed mice either treated with vehicle
or quercetin, elastase/LPS-exposed mice treated with
vehicle showed significantly increased levels of
TBARS and iNos, and decreased levels of Hmox-1
mRNA. The ratio of iNos/Hmox-1 was increased (Fig-
ures 2A to 2D). In contrast, elastase/LPS exposed
mice treated with 0.2 mg of quercetin for 10 days
showed significantly reduced TBARS, increased
Hmox-1 mRNA and decreased iNos/Hmox-1 com-
pared to vehicle treated controls. These results indi-
cate that exposure of mice to elastase/LPS increases
oxidative stress, and that treatment with quercetin
reverses this effect.
Quercetin treatment reduces lung inflammation in
elastase/LPS-exposed mice
Lung cytokine levels, histology, total and differential
cells counts in the BAL, and expression of the mucin
gene Muc5AC were determined to test whether quer-
cetin treatment reduces inflammation in elastase/LPS
exposed mice. As previously noted, elastase/LPS-
exposed mice showed increased protein expression of
the chemokines KC/CXCL-1, MIP-2/CXCL-2 and
MCP-1/CCL2 and pro-inflammatory cytokines IL-1b,
IL-12p40 and MIP-1b (Figure 3). Compared to vehi-
cle, quercetin treatment significantly decreased the
levels of all chemokines and pro-inflammatory cyto-
kines examined. PBS-exposed mice treated with quer-
cetin showed similar levels of all cytokines measured
compared to mice treated with vehicle (data not
shown).
Evaluation of H & E-stained lung sections showed
wide-spread lung inflammation and emphysema in elas-
tase/LPS exposed mice as observed previously (Figure
4A). Quercetin-treated elastase/LPS exposed mice
showed an overall reduction in lung inflammation com-
pared to vehicle treated mice (Figure 4C). Immunostain-
ing of lung sections with anti-MUC5AC antibody
showed intense signals in the airway epithelium of elas-
tase/LPS-exposed mice treated with vehicle but not
mice treated with quercetin (Figures 4B and 4D). Con-
sistent with the histologic changes, elastase/LPS-exposed
mice showed increased total cell counts, macrophages
and neutrophils compared to PBS-exposed mice, and
each of these variables was significantly reduced by
quercetin (Figure 4E). We also observed decreased
mRNA expression of Muc5AC in quercetin-treated,
elastase/LPS-exposed mice compared to vehicle-treated
mice (Figure 4F).
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Figure 1 Quercetin partially improves lung function in elastase-LPS exposed mice. Mice were anesthetized and pressure-volume
relationships, compliance and elastance were measured using flexivent system. Chord length was determined by morphometry. Seven days after
the last exposure to elastase/LPS, untreated mice showed a leftward and upward shift in the pressure-volume (PV)-loop (A) compared to PBS-
exposed vehicle treated mice, indicative of a loss of elastic recoil. Seventeen days after the last exposure to elastase/LPS, this curve shifted
further, indicating progression in the loss of elastic recoil. Quercetin treatment for 10 days prevented progression in loss of elastic recoil in
elastase/LPS-exposed mice but had no effect on PBS-exposed mice (B). Each of these mice was examined 17 days after the last elastase/LPS
treatment. Elastase/LPS-exposed mice treated with quercetin also showed increased elastance (C), decreased compliance (D) and decreased
alveolar chord length (E) compared to vehicle treated mice. Representative PV curves from 5 to 6 mice from each group are shown in A and B.
Data in C, D and E represent mean and SD calculated from 6 animals per group (*different from PBS group, p≤0.05 one-way ANOVA; † different
from vehicle treated mice, p≤0.05 Mann-Whitney test).
Ganesan et al. Respiratory Research 2010, 11:131
http://respiratory-research.com/content/11/1/131
Page 5 of 15
Quercetin treatment inhibits MMP9 and MMP12 activity
and increases Sirt1 expression
Increased MMP levels are thought to play a role in the
development and/or progression of emphysema in
COPD patients [25-27]. Consistant with this, lungs of
elastase/LPS exposed mice showed increased mRNA
and activity levels of MMP9 and MMP12 compared to
vehicle treated PBS-exposed mice (Figure 5A-C). Lung
MMP levels did not change in quercetin treated PBS-
exposed mice (data not shown). Quercetin treatment
significantly decreased the mRNA and activity levels of
both MMP9 and MMP12 in elastase/LPS-exposed
mice.
MMP9 transcription is negatively regulated by a his-
tone deacetylase, SIRT1 (2). We examined whether
reductions in Mmp9 and Mmp12 mRNA levels were
associated with increases in SIRT1 expression in querce-
tin-treated, elastase/LPS-exposed mice. Vehicle-treated
elastase/LPS-exposed mice showed an 83.2% reduction
in mRNA expression of Sirt1 compared to mice unex-
posed to elastase/LPS (Figure 5D). Similarly, we
observed 53% reduction in protein levels of Sirt1 in the
Figure 2 Quercetin treatment reduces TBARS and increases Hmox-1 expression in elastase/LPS exposed mice. Mice exposed to PBS or
elastase/LPS were orally gavaged with 0.2 mg of quercetin or vehicle daily for 10 days and sacrificed on the last day of quercetin treatment. A
to D. Elastase/LPS exposed mice show increased levels of TBARS, increased iNOS mRNA levels, decreased Hmox-1 mRNA and increased ratio of
iNOS/Hmox-1 compared to PBS exposed mice treated with either vehicle or quercetin. Quercetin treatment reduces TBARS, increases Hmox-1
mRNA and decreases ratio of iNOS/Hmox-1 in elastase/LPS-exposed mice. Data represent mean and SEM (n = 10-14, *different from PBS/vehicle
and PBS/quercetin group, p≤0.05; † different from vehicle treated elastase/LPS-exposed mice, p≤0.05 one-way ANOVA).
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lungs of vehicle-treated, elastase/LPS-exposed mice (Fig-
ure 5E and 5F). Quercetin treatment of elastase/LPS
exposed mice increased both Sirt1 mRNA and protein
levels. These results suggest that quercetin may suppress
MMP9 and MMP12 expression by increasing Sirt1
levels.
A Sirt1 inhibitor blocks the protective effect of quercetin
To determine the contribution of Sirt1 expression to the
observed effects of quercetin on lung phenotype, elas-
tase/LPS exposed mice were treated with polyethylene
glycol or quercetin along with sirtinol, an inhibitor of
Sirt1 activity [28]. As observed earlier, compared to
vehicle-treated elastase/LPS-exposed mice, lungs of
quercetin-treated mice showed reduced mRNA expres-
sion of MMP9 and MMP12 (Figure 6A and 6B) and
improved elastic recoil as indicated by leftward and
downward shift in pressure-volume loops, decreased sta-
tic compliance and increased static elastance (Figure 6C
and 6E). In contrast, mice treated with quercetin along
with sirtinol showed a similar level of MMP mRNA
expression as vehicle treated elastase/LPS mice. Sirtinol
treatment also blocked the improvements of elastic
recoil, static compliance and static elastance induced by
quercetin. These results are consistent with the notion
that quercetin exerts its effects by increasing Sirt1 levels,
which negatively regulate MMP expression.
Measurement of quercetin levels in plasma
Chromatographic analysis of plasma obtained from mice
treated with 0.2 mg quercetin for 10 days revealed a
major peak which corresponded to quercetin aglycone
and other minor peaks as we observed previously [19].
Quantification of the major peak indicated a mean
plasma quercetin level of 0.131 ± 0.038 μM in mice
treated with quercetin. This level was significantly
higher than the quercetin level observed in vehicle-trea-
ted mice (0.004 ± 0.0019 μM).
Quercetin inhibits transcription of MMP 9 and
MMP12 in alveolar macrophages in vitro
Sirt1, a histone deacetylase, negatively regulates MMP9
transcription by deacetylating histone H4 in the promo-
ter region NF-B binding site [7]. To determine whether
quercetin increases H4 deacetylation at this site, we
employed an in vitro cell culture system. Murine
Figure 3 Quercetin treatment decreases chemokine and cytokine levels in elastase/LPS exposed mice. Mice exposed to elastase/LPS
were orally gavaged with vehicle or quercetin as described. A to F. Elastase/LPS exposed mice show increased levels of KC, MIP2, MCP-1, IL-1b,
IL-12p40 and MIP-1b compared to control naïve mice. Quercetin treatment reduces all the examined cytokines and chemokines. Data represent
mean and SEM (n = 10, *different from PBS/vehicle group, p≤0.05; † different from vehicle-treated elastase/LPS exposed mice, p≤0.05 one-way
ANOVA).
Ganesan et al. Respiratory Research 2010, 11:131
http://respiratory-research.com/content/11/1/131
Page 7 of 15
Figure 4 Quercetin treatment reduces lung inflammation and reverses goblet cell metaplasia. Lung sections from elastase/LPS exposed
mice were stained with H & E or immunostained with an antibody to Muc5AC. A and B. Mice treated with vehicle show mild-to-moderate
wide-spread lung inflammation, emphysema and goblet cell metaplasia. C and D. Mice treated with quercetin show less emphysema with very
mild inflammation and a complete reduction in MUC5AC producing goblet cells. Asterisks in A and C represent emphysema. Arrows in B
indicate MUC5AC- producing goblet cells. Images are representative of 6 mice per group. E. Examination of BAL fluid reveals increased numbers
of total cells, macrophages and neutrophils in elastase/LPS treated mice, which were almost completely reversed by quercetin treatment. F.
qPCR analysis of total lung RNA shows increased Muc5AC transcript levels in elastase/LPS-exposed mice, and this was reduced in quercetin
treated mice. Data represent mean and SEM (n = 10, *different from PBS/vehicle group, p≤0.05; † different from vehicle treated elastase/LPS
exposed mice, p≤0.05 one-way ANOVA).
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Figure 5 Quercetin treatment decreases levels of MMP9 and MMP12 and increases expression of SIRT1 in elastase/LPS-exposed mice.
mRNA expression of Mmp9, Mmp12, and Sirt1 was measured by qPCR. MMP activity was determined by gelatin zymography. Sirt1 protein level
was measured in the lung homogenates by Western blot analysis. A and B. Quercetin treated elastase/LPS exposed mice show significantly
reduced Mmp9 and Mmp12 mRNA levels compared to mice treated with vehicle. C Quercetin treatment completely reduces MMP9 and MMP12
activities in elastase/LPS exposed mice. D and E. Quercetin increases Sirt1 mRNA and protein levels in elastase/LPS exposed mice. F. Ratio of Sirt1
protein/b-actin normalized to control mice calculated from 6 mice per group. Data represent mean and SEM (n = 10, *different from PBS/vehicle
group, p≤0.05; † different from vehicle-treated, elastase/LPS-exposed mice, p≤0.05 one-way ANOVA). Images in C and E are representative of
4 to 6 animals per group.
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Figure 6 Inhibition of Sirt1 activity in quercetin-treated mice attenuates querecetin-induced changes in MMP expression and
emphysema progression. Elastase/LPS-exposed mice were treated with vehicle or quercetin along with sirtinol or PBS. A and B. Mice treated
with quercetin and sirtinol did not show reduced MMP9 or MMP12 mRNA expression. Results represent range of data with median (n = 4-6,
*different from all other groups, p≤0.05; ANOVA on ranks). C-E. Sirtinol also inhibited quercetin’s effects on elastic recoil (C), compliance (D) and
elastance (E). Data represent mean and SEM (n = 4-6, *different from all other groups, p≤0.05; one-way ANOVA). C. Representative of 4-6 animals
per group.
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alveolar macrophages exposed to low levels of LPS for
three days showed increased Mmp9 and Mmp12 mRNA
levels, with a concomitant decrease in Sirt1 expression
(Figure 7A-C). We also observed increased MMP9 activ-
ity (Figure 7D) and decreased SIRT1 protein expression
(Figure 7E and 7F) in LPS-treated alveolar macrophages.
Consistent with these in vivo results, in vitro quercetin
treatment of alveolar macrophages significantly
decreased LPS-induced mRNA expression of Mmp9 and
Mmp12 as well as MMP9 activity, while increasing
mRNA and protein expression of Sirt1. Next, we exam-
ined whether quercetin increases histone deacetylation
of the MMP9 and MMP12 promoter NF-B binding
sites by ChIP assay. Histone H4 acetylation at the
MMP9 and MMP12 promoter NF-B binding sites was
increased in LPS-exposed alveolar macrophages com-
pared to media-treated controls, and this was completely
inhibited by treatment with quercetin (Figures 7G and
7H). These results suggest that quercetin inhibits H4-
acetylation of MMP promoters by increasing Sirt-1
expression, thereby regulating MMP expression at the
transcriptional level.
Discussion
We demonstrate that oral administration of quercetin, a
major flavonoid in the human diet, significantly
decreases oxidative stress and inflammation in the lungs
of elastase/LPS-treated mice, which show features typi-
cal of COPD. Quercetin also decreases MMP9 and
MMP12 levels by increasing expression of the type III
protein deacetylase Sirt-1, a negative regulator of MMP
transcription both in vivo and in vitro. Further, querce-
tin improves lung elasticity and compliance in elastase/
LPS treated mice by preventing progression of
emphysema.
In this study, mice were exposed to elastase and LPS,
rather than cigarette smoke, the primary trigger of
COPD in industrialized nations. This published murine
model system [15] produces structural and functional
features that are more pronounced and more typical of
human COPD than can be achieved in wild type mice
by even prolonged exposures to tobacco-smoke alone.
These changes include not only pulmonary emphysema,
loss of lung elastic recoil, hyperinflation, but also diffuse
lung inflammation, goblet cell metaplasia, airway remo-
deling and markedly increased numbers of neutrophils,
T and B lymphocytes, monocytes and immature macro-
phages in the airways and alveoli [15]. By contrast, mice
exposed to cigarette smoke develop pulmonary emphy-
sema and accumulation of alveolar macrophages, but
fail to demonstrate chronic bronchitis or goblet cell
metaplasia [29]. Importantly, in our model system, these
morphological and inflammatory changes were accom-
panied by increases in lung IL-1b, IL-6, TNF-a, and
MIP-2/CXCL2, markers of oxidative stress, MMP
expression and reduction in Sirt1 levels, as seen in
humans with COPD [30-32]. Moreover, LPS is a signifi-
cant constituent of cigarette smoke [9,10]. Therefore, we
believe that elastase/LPS-exposed mice are suitable for
examining the therapeutic effects of quercetin or other
potential drug candidates.
Epidemiologic studies of COPD patients have sug-
gested an association of polyphenol intake with
improved symptoms, as assessed by cough, sputum pro-
duction, breathlessness and improved lung function, as
measured by FEV1 [33-35]. Several in vitro and in vivo
studies also have showed a direct impact of polyphenols
in reducing oxidative stress and inflammation. For
instance, resveratrol, a component of red wine,
decreased inflammatory cytokine production from
macrophages isolated from COPD patients [36] and
induced synthesis of reduced glutathione by activating
NF-E2-related factor (Nrf)-2, a key antioxidant tran-
scription factor in human lung epithelial cells [37]. Cur-
cumin, another well-studied polyphenol, has also been
reported to inhibit activation of NF-B in vitro and
inflammation in vivo and restore glucocorticoid efficacy
in response to oxidative stress by upregulation of
HDAC2 activity in macrophages [38-40]. Curcumin also
increased synthesis of Nrf2-dependent phase II antioxi-
dant enzymes in elastase and cigarette smoke- exposed
mice [41]. Quercetin, which is a potent antioxidant and
possesses anti-inflammatory properties, decreased lung
oxidative stress, inflammation, and prevented progres-
sion of emphysema in elastase/LPS-exposed mice.
TBARS, products of lipid peroxidation and an index of
oxidative stress caused by reactive oxygen species, have
been shown to be increased in COPD patients [30]. In
addition, the number of HMOX-1 expressing alveolar
macrophages is markedly decreased in patients with
severe COPD, while iNOS expression is increased in
alveolar and bronchial epithelial cells [42]. Increased
staining for the nitration marker nitrotyrosine in iNOS
positive cells was observed in induced sputum from
patients with moderate stable COPD compared to non-
smokers [43]. Finally, overexpression of HMOX-1 in
mouse lungs was shown to suppress elastase-induced
emphysema by attenuating neutrophilic inflammation
[44]. In the present study, quercetin treatment of elas-
tase/LPS-exposed mice increased the expression of
Hmox-1 and tended to decrease the expression of iNOS.
Consistent with our observation, quercetin was noted to
inhibit iNOS expression and NO production in LPS and
interferon-g-treated mouse BV-2 microglial cells, and
this was associated with elevated expression of Hmox-1
[45-47]. Together, these data suggest that quercetin may
inhibit chemokine and pro-inflammatory cytokine pro-
duction in elastase/LPS exposed mice not only by
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Figure 7 Quercetin decreases MMP9 and MMP12 and increases Sirt1 in LPS-treated alveolar macrophages. Mouse alveolar macrophages
were treated with LPS (1 ng/ml) for 3 days and treated with DMSO (vehicle) or 25 µM quercetin for 16 h. A and B. LPS treatment induced
mRNA expression of MMP9 and MMP12 which are partially reversed by quercetin. C and E. Quercetin increases Sirt1 mRNA and protein
expression. D. MMP9 activity in LPS-exposed was abrogated by quercetin treatment. E. A representative Western blot showing Sirt1 and b-actin
expression. F. Ratio of Sirt1 protein/b-actin normalized to untreated cells calculated from 3 independent experiments. G and H. Quercetin
decreased LPS-induced histone H4 acetylation at the NF-B binding sites in the promoter regions of both Mmp9 and Mmp12. Zymogram and
immunoblot images are representative of three independent experiments. Data represent mean and SEM calculated from 3 independent
experiments performed in duplicates or triplicates (*different from macrophages exposed to media in the absence of quercetin, p≤0.05;
†different from LPS-exposed macrophages which are not treated with quercetin, p≤0.05 one-way ANOVA).
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scavenging the free radicals, but also by increasing the
expression of Hmox-1, which suppresses iNOS expres-
sion [48].
In our study, quercetin treatment of elastase/LPS-
exposed mice was accompanied by significant
decreases in the levels of neutrophil attracting C-X-C
chemokines KC and MIP-2, monocyte and macrophage
chemoattractant MCP-1 and pro-inflammatory cyto-
kines including IL-1b, IL12p40 and MIP-1b. In addi-
tion to its antioxidant effects, quercetin may attenuate
lung inflammation by inhibition of protein and lipid
kinases involved in inflammatory cytokine and chemo-
kine production. Quercetin has inhibitory effects on
phosphatidylinositol 3-kinase, AMP-activated kinase,
casein kinase 2, p90 ribosomal protein S6 kinase, p70
ribosomal S6 kinase [49], protein kinase C [50], epider-
mal growth factor receptor tyrosine kinase [51] and
IB kinase [52]. Indeed, the design of the synthetic PI
3-kinase inhibitor LY294002 was based on the struc-
ture of quercetin [53].
Another important finding of this study was that quer-
cetin inhibited MMP expression in elastase/LPS treated
mice. MMP expression is increased in COPD patients
and plays a critical role in development and progression
of emphysema. MMP also increases mucin production,
leading to airway obstruction [54-58]. Further, levels of
Sirt1, a type III histone deacetylase which negatively reg-
ulates MMP9 transcription [7], were reported to be
downregulated in patients with severe COPD but not in
healthy smokers, suggesting a role for endogenous oxi-
dative stress from activated neutrophils and macro-
phages in the reduction of Sirt1 [7]. Further, treatment
of cigarette smoke-exposed mice with Sirt1 activator
blocked MMP9 expression and pulmonary neutrophilic
inflammation. In the present study, we found that elas-
tase/LPS treatment increased expression and activity of
MMP9 and MMP12. Interestingly, we also found
decreased levels of the protein deacetylase Sirt1 in these
mice. Quercetin treatment decreased MMP9 and
MMP12 levels in elastase/LPS-exposed mice, while con-
comitantly increasing mRNA and protein levels of Sirt1,
suggesting that quercetin may decrease MMP expression
via deacetylation at the MMP promoter. Consistent with
this, we observed that, in alveolar macrophages. querce-
tin decreases LPS-induced histone H4 acetylation at the
MMP9 and MMP12 promoter NF-B binding sites,
thereby decreasing the transcription of MMP9 and
MMP12. Furthermore, sirtinol, which inhibits Sirt1
activity, abrogated the effect of quercetin on MMP levels
and lung elasticity in elastase/LPS-exposed mice.
Together, these data suggest that quercetin prevents
further degradation of alveolar walls by decreasing
MMP expression, thereby slowing the progression of
emphysema in these mice
Quercetin doses ranging between 10 to 100 mg/kg
body weight have been used in previous animal studies
of allergic airways disease [19,20,59]. Beneficial effects of
quercetin were observed at doses as low as 10 mg/kg
body weight. For example, we showed that 0.2 mg
(approximately 10 mg/kg) inhibited eosinophilic inflam-
mation and airways responsiveness in cockroach aller-
gen-sensitized and challenged mice [19]. At this dose,
quercetin levels of 0.25 μM were achieved. In the pre-
sent study, plasma quercetin levels of 0.131 μM were
reached. This dose was well-tolerated and was sufficient
to prevent progression of emphysema. Our previous
study showed that quercetin concentrations as low as
0.1 μM suppress airway epithelial cell cytokine expres-
sion in vitro [19]. It is also possible that enteral adminis-
tration of quercetin produces sufficient gut levels to
modulate lung inflammation, perhaps by altering the
microbiome. Normally, human quercetin plasma con-
centrations are in the low nanomolar range, but upon
supplementation it may increase to the high nanomolar
or low micromolar range [60], suggesting that the con-
centration of quercetin required to prevent progression
of emphysema can be achieved in humans. It is possible
that absorption and availability can be further increased
by using glycosylated form of quercetin [61]. These
levels of quercetin were reported to be safe in humans
with no adverse effects (reviewed in [62]). On the other
hand, a handful of in vitro studies suggested that quer-
cetin metabolites may be harmful and in fact may
increase oxidative stress in lung epithelial cells [63,64].
Further studies are needed to determine the appropriate
dosage and form of quercetin (glycosylated versus agly-
cosylated) for administration to human patients.
Conclusions
In summary, we have demonstrated that quercetin, a
plant polyphenol, reduces oxidative stress, inflammation
and MMP levels in elastase/LPS treated mice which
show typical features of COPD. Quercetin also pre-
vented progression of emphysema in these mice. Even
after cessation of smoking, COPD patients show pro-
gressive emphysematous changes due to persistent oxi-
dative stress and protease burden in the airways [24].
The possibility that quercetin, which reduces inflamma-
tion and MMP levels while preventing progression of
emphysema, may be beneficial in patients with COPD
merits clinical testing.
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